This study is testing a new treatment called sacituzumab tirumotecan for people with ovarian cancer that has come back and responds to platinum treatment. The study will see if this treatment, with or without another drug called bevacizumab, helps people live longer without the cancer getting worse compared to the usual treatment.

Sacituzumab tirumotecan is a medicine designed to target and kill cancer cells. Bevacizumab is a drug that stops the growth of new blood vessels that cancer needs to grow. The study will also check if the treatment is safe and if patients can handle it well.

• The study includes people who have certain types of ovarian cancer and have had specific treatments before.
• Participants must be in good health and not have certain other health issues, like severe eye conditions or active infections.
• Participants should not have more than 2 prior lines of therapy for ovarian cancer and should not have received recent cancer treatments.